Skip to main content
SpringerLink
Log in

Targeted Treatment of Renal Cell Carcinoma

  • Chapter
  • First Online:
Book cover Kidney Cancer

Abstract

The management of patients with metastatic RCC (mRCC) has been completely changed in the last decade by the introduction of novel molecularly targeted approaches. Although partial or radical nephrectomy still remains the standard approach for patients with localized RCC, systemic therapies are recommended in patients with mRCC. Till 2005, cytokine therapies represented the gold standard but were associated with a poor toxicity profile and a low response rate. Successively, the growing knowledge of the key role of angiogenesis in the development and progression of mRCC has led to the development of several targeted agents, which have increased the life expectancy of these patients. In this chapter, we describe the main agents currently used into daily clinical practice and the results of the clinical studies that have led to their approval in patients with mRCC.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Presta LG, Chen H, O’Connor SJ, Chisholm V, Meng YG, Krummen L, et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 1997;57:4593–9.

    CAS  PubMed  Google Scholar 

  2. Escudier B, Bellmunt J, Negrier S, Bajetta E, Melichar B, Bracarda S, et al. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol. 2010;28:2144–50. https://doi.org/10.1200/JCO.2009.26.7849.

    Article  CAS  PubMed  Google Scholar 

  3. Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Archer L, et al. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol. 2010;28:2137–43. https://doi.org/10.1200/JCO.2009.26.5561.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Hainsworth JD, Spigel DR, Burris HA III, Waterhouse D, Clark BL, Whorf R. Phase II trial of bevacizumab and everolimus in patients with advanced renal cell carcinoma. J Clin Oncol. 2010;28:2131–6. https://doi.org/10.1200/JCO.2009.26.3152.

    Article  CAS  PubMed  Google Scholar 

  5. Negrier S, Gravis G, Perol D, Chevreau C, Delva R, Bay JO, et al. Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial. Lancet Oncol. 2011;12:673–80. https://doi.org/10.1016/S1470-2045(11)70124-3.

    Article  CAS  PubMed  Google Scholar 

  6. Rini BI, Bellmunt J, Clancy J, Wang K, Niethammer AG, Hariharan S, et al. Randomized phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial. J Clin Oncol. 2014;32:752–9. https://doi.org/10.1200/JCO.2013.50.5305.

    Article  CAS  PubMed  Google Scholar 

  7. Harshman LC, Barbeau S, McMillian A, Srinivas S. A phase II study of bevacizumab and everolimus as treatment for refractory metastatic renal cell carcinoma. Clin Genitourin Cancer. 2013;11:100–6. https://doi.org/10.1016/j.clgc.2012.12.002.

    Article  PubMed  Google Scholar 

  8. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356:125–34. https://doi.org/10.1056/NEJMoa060655.

    Article  CAS  PubMed  Google Scholar 

  9. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Staehler M, et al. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol. 2009;27:3312–8. https://doi.org/10.1200/JCO.2008.19.5511.

    Article  CAS  PubMed  Google Scholar 

  10. Hutson TE, Escudier B, Esteban E, Bjarnason GA, Lim HY, Pittman KB, et al. Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2014;32(8):760–7. https://doi.org/10.1200/JCO.2013.50.3961.

    Article  CAS  PubMed  Google Scholar 

  11. Haas NB, Manola J, Uzzo RG, Atkins MB, Wilding G, Pins M, et al. Initial results from ASSURE (E2805): adjuvant sorafenib or sunitinib for unfavorable renal carcinoma, an ECOG-ACRIN-led, NCTN phase III trial. J Clin Oncol. 2015;33. Suppl 7; abstr 403:403. https://doi.org/10.1200/jco.2015.33.7_suppl.403.

    Article  Google Scholar 

  12. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009;27:3584–90. https://doi.org/10.1200/JCO.2008.20.1293.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Ravaud A, Motzer RJ, Pandha HS, George DJ, Pantuck AJ, Patel A, et al., S-TRAC investigators. Adjuvant sunitinib in high-risk renal-cell carcinoma after nephrectomy. N Engl J Med. 2016;375:2246–2254. doi: https://doi.org/10.1056/NEJMoa1611406.

    Article  CAS  Google Scholar 

  14. Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol. 2010;28:1061–8. https://doi.org/10.1200/JCO.2009.23.9764.

    Article  CAS  PubMed  Google Scholar 

  15. Sternberg CN, Hawkins RE, Wagstaff J, Salman P, Mardiak J, Barrios CH, et al. A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update. Eur J Cancer. 2013;49:1287–96. https://doi.org/10.1016/j.ejca.2012.12.010.

    Article  CAS  PubMed  Google Scholar 

  16. Escudier B, Porta C, Bono P, Powles T, Eisen T, Sternberg CN, et al. Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES Study. J Clin Oncol. 2014;32:1412–8. https://doi.org/10.1200/JCO.2013.50.8267.

    Article  CAS  PubMed  Google Scholar 

  17. Hainsworth JD, Rubin MS, Arrowsmith ER, Khatcheressian J, Crane EJ, Franco LA. Pazopanib as second-line treatment after sunitinib or bevacizumab in patients with advanced renal cell carcinoma: a Sarah Cannon Oncology Research Consortium Phase II Trial. Clin Genitourin Cancer. 2013;11:270–5. https://doi.org/10.1016/j.clgc.2013.04.006.

    Article  PubMed  Google Scholar 

  18. Motzer R, Haas NB, Donskov F, Gross-Goupil M, Varlamov S, Kopyltsov E,et al. Randomized phase III trial of adjuvant pazopanib versus placebo after nephrectomy in patients with locally advanced renal cell carcinoma (RCC) (PROTECT). J Clin Oncol. 2017;35 Suppl 15:abstr 4507. doi: https://doi.org/10.1200/JCO.2017.35.15_suppl.4507.

    Article  Google Scholar 

  19. Rini BI, Escudier B, Tomczak P, Kaprin A, Szczylik C, Hutson TE, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet. 2011;378:1931–9. https://doi.org/10.1016/S0140-6736(11)61613-9.

    Article  CAS  PubMed  Google Scholar 

  20. Motzer RJ, Escudier B, Tomczak P, Hutson TE, Michaelson MD, Negrier S, et al. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. Lancet Oncol. 2013;14:552–62. https://doi.org/10.1016/S1470-2045(13)70093-7.

    Article  CAS  PubMed  Google Scholar 

  21. Hutson TE, Lesovoy V, Al-Shukri S, Stus VP, Lipatov ON, Bair AH, et al. Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial. Lancet Oncol. 2013;14:1287–94. https://doi.org/10.1016/S1470-2045(13)70465-0.

    Article  CAS  PubMed  Google Scholar 

  22. Choueiri TK, Escudier B, Powles T, Tannir NM, Mainwaring PN, Rini BI, et al., METEOR investigators. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. Lancet Oncol 2016;17:917–927. doi: https://doi.org/10.1016/S1470-2045(16)30107-3.

    Article  CAS  Google Scholar 

  23. Choueiri TK, Halabi S, Sanford BL, Hahn O, Michaelson MD, Walsh MK, et al. Cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk: the alliance A031203 CABOSUN trial. J Clin Oncol. 2017;35:591–7. https://doi.org/10.1200/JCO.2016.70.7398.

    Article  CAS  PubMed  Google Scholar 

  24. Molina AM, Hutson TE, Larkin J, Gold AM, Wood K, Carter D, et al. A phase 1b clinical trial of the multi-targeted tyrosine kinase inhibitor lenvatinib (E7080) in combination with everolimus for treatment of metastatic renal cell carcinoma (RCC). Cancer Chemother Pharmacol. 2014;73:181–9. https://doi.org/10.1007/s00280-013-2339-y.

    Article  CAS  PubMed  Google Scholar 

  25. Atkins MB, Hidalgo M, Stadler WM, Logan TF, Dutcher JP, Hudes GR, et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol. 2004;22:909–18. https://doi.org/10.1200/JCO.2004.08.185.

    Article  CAS  PubMed  Google Scholar 

  26. Raymond E, Alexandre J, Faivre S, Vera K, Materman E, Boni J, et al. Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI- 779, a novel mTOR inhibitor, in patients with cancer. J Clin Oncol. 2004;22:2336–47. https://doi.org/10.1200/JCO.2004.08.116.

    Article  CAS  PubMed  Google Scholar 

  27. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007;356:2271–81. https://doi.org/10.1056/NEJMoa066838.

    Article  CAS  PubMed  Google Scholar 

  28. Ravaud A, Barrios CH, Alekseev B, Tay MH, Agarwala SS, Yalcin S, et al. RECORD-2: phase II randomized study of everolimus and bevacizumab versus interferon a-2a and bevacizumab as first-line therapy in patients with metastatic renal cell carcinoma. Ann Oncol. 2015;26:1378–84. https://doi.org/10.1093/annonc/mdv170.

    Article  CAS  PubMed  Google Scholar 

  29. Motzer RJ, Barrios CH, Kim TM, Falcon S, Cosgriff T, Harker WG, et al. Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma. J Clin Oncol. 2014;32:2765–72. https://doi.org/10.1200/JCO.2013.54.6911.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373:1803–13. https://doi.org/10.1056/NEJMoa1510665.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Hammers HJ, Plimack ER, Infante JR, et al. Safety and efficacy of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma: the CheckMate 016 Study. J Clin Oncol. 2017;35:3851–8. https://doi.org/10.1200/JCO.2016.72.1985.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Oncology Unit, Macerata Hospital, Macerata, Italy

    Matteo Santoni & Nicola Battelli

  2. Institute of Pathological Anatomy and Histopathology, University of the Marche Region, Ancona, Italy

    Alessia Cimadamore

  3. Departments of Pathology, Urology, and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN, USA

    Liang Cheng

  4. Department of Pathology and Surgery, Cordoba University School of Medicine, Córdoba, Spain

    Antonio Lopez-Beltran

  5. Institute of Pathological Anatomy and Histopathology, United Hospitals, Ancona, Italy

    Marina Scarpelli & Rodolfo Montironi

Authors
  1. Matteo Santoni
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alessia Cimadamore
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Liang Cheng
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Antonio Lopez-Beltran
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Marina Scarpelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Nicola Battelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Rodolfo Montironi
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Weill Medical College of Cornell University, Houston, TX, USA

    Mukul K. Divatia

  2. Gulhane Military Medical Academy, School of Medicine, Department of Pathology, Ankara, Turkey

    Ayhan Ozcan

  3. Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

    Charles C. Guo

  4. Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Weill Medical College of Cornell University, Houston, TX, USA

    Jae Y. Ro

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Santoni, M. et al. (2020). Targeted Treatment of Renal Cell Carcinoma. In: Divatia, M., Ozcan, A., Guo, C., Ro, J. (eds) Kidney Cancer. Springer, Cham. https://doi.org/10.1007/978-3-030-28333-9_19

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-28333-9_19

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-28332-2

  • Online ISBN: 978-3-030-28333-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation